The Peptide Paradox: How Restricting Safe Clinical Access Made the Wild West Bigger

---

The physician doing it right gets burdened. The gray market gets a pass. That’s not a safety system. That’s a supply-chain problem wearing a safety system’s clothing.

---

Sometime in the last three months, I re-sourced my GLP-1s for the third time.

Not because the compounds changed. Not because the clinical evidence shifted. Not because anyone demonstrated harm. A compounding pharmacy I’d been relying on stopped shipping to Virginia. Then one of the ones I switched to stopped carrying the formulation I needed. Then the federal rules shifted again.

Each time, the process restarts: identify a new pharmacy, require a certificate of analysis, verify the price hasn’t inflated along with the scarcity, confirm what’s actually in the vial matches what the label says.

I’ve been doing this resourcing for nearly twenty years. I started using GLP-1s clinically in 2006, back when Byetta required twice-daily injections and nobody outside of endocrinology was paying attention. I practiced in the military before building a functional medicine practice around some of the most complex, treatment-resistant patients I’ve encountered. I am not someone who discovered these compounds through a podcast three years ago.

I’m also not someone who’s immune to the biology I’m describing. At 53, my body is starting to look a little different. I’m carrying more around the middle than I used to. I don’t heal at the rate I healed at 35. I know what declining growth hormone signaling feels like because I’m living it. Most useful clinical knowledge eventually becomes personal, if you practice long enough.

Meanwhile, a patient I’m currently working with in California can walk into a vape shop and buy the same compounds off the street.

---

These Aren’t Experimental Compounds

The word “experimental” gets attached to peptide therapy so reflexively that it’s worth pausing to examine what it actually means.

The first peptide ever used therapeutically was insulin. We’ve been extracting it from pigs and injecting it into human beings since the 1950s. The foundational treatment for type 1 diabetes, practiced for seventy years, given to hundreds of millions of people. If the concept of “peptide therapy” feels biologically alien or inherently risky, that’s the first assumption worth revisiting.

Thymosin Alpha-1 was isolated from thymus tissue in the 1970s by Alan Goldstein’s group at George Washington University. It’s been approved for human use in thirty-five countries. Physicians around the world use it for hepatitis B, hepatitis C, and cancer support, specifically to help maintain white cell counts when chemotherapy drives them down. There are over 11,000 human subjects in the published trial record. The compound has been around for fifty years.

It’s not approved in the United States. Not because there is a lack of evidence. Because no pharmaceutical company has invested the resources required to run it through the U.S. approval pathway. That’s a structural reality about how medical legitimacy gets conferred in this country, not a statement about the compound’s safety profile.

BPC-157 was originally isolated from gastric juice. TB-500 is a derivative of thymosin beta-4, discovered by the same research group at George Washington. CJC is a growth hormone secretagogue that works by restoring the body’s own pulsatile GH rhythm. These compounds have been used in functional medicine for decades. Clinicians I respect have been using them carefully, in appropriate patient populations, with documented outcomes, for longer than most of the online conversation about peptides has existed.

I stick with the stuff that’s been tried and true. There is so much out there right now. New compounds, newer compounds, things that have been around for a year with exciting preliminary data and a lot of social media momentum. I don’t chase those. The good old-fashioned BPC, TB4, Thymosin Alpha-1. These have decades behind them. Why jump to the fancy new thing when the compounds that have been around forever and actually work are sitting right there, increasingly hard to access? That conservatism isn’t timidity. It’s what nearly twenty years of clinical experience produces.

In September 2023, the FDA added nineteen peptides to a restricted category, effectively banning their use in compounding pharmacies. The list included BPC-157, Thymosin Alpha-1, TB-500, CJC, epitalon, MOTS-c, and others.

One month later, tirzepatide was approved for weight loss.

The timing reflects something real about how the approval pathway works: compounds that can generate pharmaceutical-scale returns move through the system; compounds that cost pennies to compound and carry no patent protection don’t. That’s not a conspiracy — it’s institutional logic. You can draw your own conclusions on that one.

---

How the Categories Work

The FDA organizes peptides for compounding into three categories:

• Category 1 compounds are considered safe for compounding pharmacies to prepare and dispense.
• Category 2 compounds are restricted: their compounding has been blocked.
• Category 3 compounds sit in a holding pattern: insufficient evidence for a determination either way.

The Category 2 designation is where things get complicated. The official framing is safety: these compounds have been deemed too risky for compounding. But if you look at the list, you find a recurring pattern. Many of the compounds placed in Category 2 aren’t there because someone demonstrated they caused harm. They’re there because they’re either entering the pharmaceutical pipeline (becoming drugs in the formal approval sense) or because someone in the regulatory process decided they belonged in a more restricted category.

The question I’ve been asking out loud for years: is it really that they’re risky, or is it that they’re getting ready to become drugs? Those are different things. And the answer to that question determines whether Category 2 is a safety classification or a market-protection mechanism.

The Cerebrolysin story is instructive. I’ve used it clinically for concussions and traumatic brain injuries, with well-documented neuroprotective effects. Cerebrolysin has more than fifty amino acids. That matters because the FDA drew an administrative line at fifty amino acids, defining anything above it as a “biologic” subject to an entirely different regulatory framework. A few years ago, Cerebrolysin crossed that line in reclassification and disappeared from compounding availability essentially overnight. Not because the clinical evidence changed. Not because it stopped working. Because it exceeded an administratively established number and was placed in a different institutional category.

The economics reinforce the structural tilt. Simply showing up before the FDA to advocate for a compound’s status costs anywhere from $100,000 to $250,000. Most of the compounds we’re discussing cost a fraction of that to compound. The approval pathway systematically favors interventions that can generate pharmaceutical-scale returns. Biologically familiar compounds with no patent protection, available inexpensively through compounding, are structurally disadvantaged in a system built around the economics of drug development.

The system rewards what it was designed to reward. Peptides just don’t fit the design.

---

The Paradox

Restricting access to peptides through licensed compounding channels doesn’t reduce demand. It relocates it.

I work with compounding pharmacies in Texas, Nevada, Florida, Indiana, Virginia, and Alabama. Not one of them ships to California. The regulatory environment in that state has made it impossible. I can’t get a clean, verified, professionally compounded peptide to a patient in California through any of the legitimate channels I’ve spent years building and vetting.

But that patient in California can walk into a vape shop and buy peptides off the street.

The gray market didn’t appear despite the crackdown. It expanded because of it. When legitimate clinical access narrows, demand doesn’t disappear. It finds another path. That path is online purchasing with no physician oversight, no certificate of analysis, no verified purification, no accountability for contamination, and no mechanism for tracking what happens if something goes wrong.

The real risk in peptides isn’t molecular. The biology of most of these compounds is familiar, sometimes identical to what the body already produces. The risk lives in the supply chain. The vast majority of peptides in circulation today, including many used in clinical settings, are synthesized in facilities in China using solvent-based chemical reactions. Making the peptide chain is straightforward. The purification process that follows is where the genuine technical difficulty and cost lives. It requires removing residual solvents, byproducts, and chemical adulterants before anything is safe for human use. Research-grade and pharmaceutical-grade peptides differ primarily in the rigor of that purification. A cheaper product isn’t just less potent. It may contain contaminants that are biologically active in ways no one anticipated.

The safety system that was designed to protect people from this risk has instead created a landscape where the pathway with no purification standards, no physician oversight, and no accountability is the most accessible one. And the pathway with all of those protections is the one being systematically narrowed: licensed physician, vetted compounding pharmacy, certificate of analysis, ongoing monitoring.

---

What Responsible Evidence-Building Actually Looks Like

VIP (vasoactive intestinal peptide) is a compound I use regularly in patients with mold illness, chronic biotoxin exposure, and traumatic brain injuries. When the September 2023 crackdown arrived and swept nineteen compounds into restricted categories, VIP survived. It remained Category 1, available for compounding.

It survived because of a specific body of work.

Dr. Shoemaker, Dr. Heyman, and the practitioner group I’m part of had spent years collecting controlled safety data on VIP use. We weren’t just using it clinically and assuming it was fine. We were tracking outcomes, documenting encounters, building the kind of evidence record that the institutional system says it wants. By the time the crackdown came, we had records on over 10,000 patient encounters. We had something to bring to the FDA. We brought it. That data is what protected VIP when everything else was being swept into restriction.

I am genuinely proud of that work. It required years of coordinated effort from a community of practitioners who were organized, motivated, and resourced enough to sustain a long-term clinical data-collection project and then engage the FDA directly. It required absorbing the cost and time of institutional engagement that most individual clinicians can’t shoulder. It was exceptional, and I don’t mean that modestly. It was extraordinary relative to what most practitioners and most compounds can sustain.

The VIP story illustrates what’s required to make the system work even partially. And why that bar is unreachable for most clinically useful compounds that lack pharmaceutical-industry backing. The compounds that survive institutional scrutiny tend to be the ones that happened to be in the hands of practitioners who were already organized enough, connected enough, and capitalized enough to run an evidence-gathering operation on something that costs almost nothing to compound.

Most clinical experience with most peptides doesn’t have that.

---

What This Controversy Is Actually About

The peptide controversy isn’t really about peptides.

These compounds keep defying the categories that modern medical and regulatory systems depend on. They are simultaneously biologically familiar and chemically synthesizable. They are naturally occurring and pharmaceutically active. They are supplement-adjacent and drug-adjacent. They are endogenous biology (the body already makes them, continuously) and they are clinical interventions when used therapeutically. They blur the lines between nutrition, signaling, supplementation, and pharmacology in ways that create genuine institutional discomfort.

Modern regulatory systems were built around cleaner distinctions: “drug” or “not-drug.” Approved mechanism or speculation. Natural or synthetic. Peptides don’t stay in any of those boxes. And when a molecule sits in the ambiguous middle ground between food, signaling biology, and pharmaceutical intervention, the institutional default tends to be restriction. Not because the biology demands it. Because ambiguity creates liability, and compounds without patent protection don’t have pharmaceutical lobbyists to manage that liability on their behalf.

Interventions that operate at the level of signaling will face versions of this same structural problem: microbiome-based therapies, exosome treatments, nutraceuticals with genuine mechanistic depth. The medical system was built to evaluate isolated mechanisms and discrete disease targets. It wasn’t built for interventions that work by nudging overlapping communication systems in a direction the body already knows.

This series started with GLP-1s because they offered a visible entry point into a larger question: what if chronic illness is increasingly a signaling problem? What if many of the conditions that fill our waiting rooms represent not isolated organ failures but failures in the communication architecture that coordinates biological function across systems? The POTS. The MCAS. The chronic fatigue, the inflammatory dysregulation, the slow recovery, the tissue that won’t heal.

If that’s true, then the tools most likely to matter are ones that work at that signaling level. And the institutions most likely to struggle are ones organized around the older framework: one disease, one mechanism, one drug.

The peptide controversy is one data point in a much larger question about whether medicine can build frameworks adequate to the biology it’s actually encountering.

---

What This Means in Practice

None of this is an argument for going to the internet and sourcing peptides yourself. I want to be direct about that, because I’ve spent this entire article explaining why gray-market sourcing is the actual problem. Not the solution.

The reckless end of peptide culture is a real problem, and it’s part of what drove the regulatory overcorrection.

Look around the current landscape. It’s peptides for everybody. No matter what’s wrong with you, someone online is suggesting a peptide for it. There’s no voice in the room saying “be careful.” Nobody’s saying take it easy. Everybody’s throwing things at the wall. I see patients who’ve been sold growth hormone peptides with an active cancer history. I see younger patients in their late teens and early twenties reaching for peptides when what they actually have is a nutritional deficiency, a sleep problem, or a gut issue they’ve never investigated. Skipping the foundational work and going straight to the peptide doesn’t fix the underlying problem. It postpones the investigation while the real cause keeps running.

The regulatory system overreached. And some of what it was responding to was worth responding to. Both things are true.

The foundation still comes first. Sleep. Real food. Protein quality. Gut integrity. Removing the chemical and toxic burden that disrupts the signaling environment in the first place. If you’re not lifting heavy weights and getting adequate sleep, why are you reaching for a growth hormone peptide? Those are the biggest levers for GH that exist. And they’re free. Peptides built on top of a compromised foundation underperform.

But for patients who have done that work and are still not recovering, whose repair signaling appears insufficient, whose inflammatory baseline stays elevated despite everything, whose bodies have stopped coordinating recovery the way they used to, the signaling layer is worth understanding seriously.

Responsible Peptide Therapy

What does working with that layer responsibly look like? I start with a primary target. Is it the immune system? Leaky gut? Chronic inflammation? Healing from an old injury? A traumatic brain injury from three or five years ago that never fully resolved? That target determines which compounds are relevant. Then I identify how I’m going to quantify what I’m doing. If I start a peptide protocol without an endpoint I’m tracking, I have no way of knowing whether it’s helping. In TBI patients that’s usually MRI findings, neurocognitive testing, and clinical response together. In COVID patients it was inflammatory markers. In patients with gut pathology it’s symptom progression and mucosal healing indicators. The compound is only one part of it. The framework around the compound is what makes the difference between clinical medicine and guesswork.

The right response to a broken access landscape is finding a clinician who works that way. Who starts with a target. Who requires a certificate of analysis before prescribing. Who monitors outcomes against something measurable. Who has sourcing relationships built over years, not assembled from a quick internet search. Who will tell you when you’re not a candidate, because active cancer, recent cancer history, pregnancy, and certain family histories are genuine contraindications that the optimization-culture conversation almost never mentions.

That’s what this kind of medicine looks like when it’s done right. It’s more work than writing a prescription for a commercially approved drug. It requires more clinical judgment, more sourcing vigilance, and more tolerance for institutional friction. But for the patients who have been failed by the system that was supposed to help them, it’s the work that finally moves the needle.

---

The Question the Series Has Been Building Toward

We started this series with a simple reframe: GLP-1s aren’t appetite suppressants. They’re systemic signaling regulators, and their most important effects may have nothing to do with weight.

That reframe opened a larger question: what if signaling is the more fundamental level of organization in chronic illness? What if the body stops recovering not because something breaks catastrophically, but because the communication systems that coordinate recovery gradually go quiet?

If that’s right — and I believe after two decades of caring for these patients that it increasingly is — then the tools that matter are ones that work at the level of communication, not just mechanism. And the institutions that matter are ones organized around that model of biology, not the older one.

The peptide controversy is, at bottom, a collision between those two models. One model says: a compound is legitimate when it has been through the formal approval pathway, demonstrated a discrete mechanism in a controlled trial, and been assigned a specific indication. The other model says: a molecule that the body already depends on, that works by restoring signaling coherence in disrupted systems, that has been used carefully by trained clinicians across decades, deserves to be evaluated on different terms.

That tension isn’t going to resolve quickly. Biology is moving faster than institutions. It usually does.

What I know is this: the patients who have changed my thinking the most are not the ones who responded to the standard protocols. They’re the ones who didn’t respond. Who did everything right and still weren’t getting better, until we started asking different questions at a different level of the biology.

Those patients are why I keep re-sourcing. Why I keep vetting pharmacies. Why I keep doing the administrative work that the system makes harder every few months.

There’s a mantra in medicine (from the Hippocratic Oath): first, do no harm. It sounds simple. In practice, in the current peptide landscape, it’s anything but. It means using compounds with real evidence behind them, not chasing novelty. It means knowing your patient’s cancer history before you prescribe a growth hormone peptide. It means requiring a certificate of analysis every single time, even when the sourcing feels stable. It means telling a twenty-year-old who wants to optimize their recovery that what they actually need is to fix their sleep and eat enough protein. The peptide will be there later if they still need it.

It also means keeping the legitimate path open, even when the system keeps making it harder. Because the alternative is not a safe outcome. A landscape where the only available access is unvetted, unmonitored, and unsourced is not a safe outcome. It’s just a quiet one.

That’s what I’m trying to hold onto. Not just access to these compounds, but access to them done right.

---